LAUSR

3871 Content in this section does not reflect any official policy or medical opinion of the American Cancer Society or of the publisher unless otherwise noted. © American Cancer Society, 2017. • The rate at which patients with samples in the AACR Project GENIE registry would match the arms of the NCIMATCH (National Cancer Institute Molecular Analysis for Therapy Choice) trial was reflected in the actual accrual rates for the trial. • Details of 2 additional studies link certain genetic characteristics of metastatic breast cancer with clinical and pathological features of the tumors in addition to patient outcomes. Charles Sawyers, MD, chair of the Human Oncology and Pathogenesis Program at the Memorial Sloan Kettering Cancer Center in New York and chair of the project’s steering committee, says that the article illustrates how Project GENIE is delivering on its promise of data-sharing initiatives to accelerate cancer discoveries and research. He adds that researchers are particularly pleased with the high number of study samples and rate of clinical actionability, which indicate that tumor genome sequencing can play a major role in clinical care. AACR Project GENIE is a multiphase, multiyear, international data-sharing initiative that was launched by AACR in partnership with 8 global academic leaders in clinical cancer genomics in November 2015. In January 2017, the consortium made public nearly 19,000 de-identified records from patients who were treated at the institutions participating in the first phase of the project. The article describes the consortium and provides a landscape overview of the first public data release, according to one of the authors, Ethan Cerami, PhD, of the DanaFarber Cancer Institute in Boston, Massachusetts. By demonstrating that the institutions could share data across the United States, Canada, and Europe to obtain results none could generate alone, the collaborators have shown the value of the project, he notes. The high-level analysis of the records shows similarities to The Cancer Genome Atlas, although the article also highlights several differences with those data, the authors say. They speculate that the differences are a result of a greater proportion of AACR Project GENIE records coming from patients with recurrent or relapsing disease.